Trevi Therapeutics (TRVI) Tops Q2 EPS by 1c

Trevi Therapeutics (NASDAQ: TRVI) reported Q2 EPS of ($0.09), $0.01 better than the analyst estimate of ($0.10).

For earnings history and earnings-related data on Trevi Therapeutics (TRVI) click here.

You May Also Be Interested In

• Royal Caribbean to acquire 50% stake in Sandals Resorts for $3 billion
• Raymond James Financial (RJF) call put ratio 1 call to 4.8 puts with a focus on May 140 and 150 puts
• SoFi Technologies (SOFI) 2300 contracts of September 17 calls and October 16 puts trade